PALO ALTO, Calif., June 5, 2020 – Neumentum, Inc., a pharmaceutical company dedicated to transforming the way pain is treated – without opioids – today announced that Scott Shively, Chief Executive Officer, has posted a presentation for digital viewing for the BIO Digital Conference scheduled for June 8-12th. The presentation provides an overview of Neumentum, key clinical program information and updates on the company’s two lead compounds, NTM-001, a novel, alcohol-free formulation of ketorolac in a pre-mixed bag for continuous IV infusion that has the potential to treat moderately severe acute pain that requires analgesia at the opioid level for up to 24 hours, usually in a postoperative setting, and NTM-006, a novel oral analgesic product that is neither an opioid nor a NSAID which was licensed from Johnson & Johnson and is under development  for moderate to moderately severe neuropathic pain.

Presentation details are as follows:

 

Date:              June 8 – 12, 2020
Location:        Presentation Available On-Demand
Link:               https://www.bio.org/events/bio-digital/sessions/676575

For 2020, the BIO International Convention has transitioned to a new, virtual event format, BIO Digital. This virtual gathering of the global biotech industry provides access to key partners via BIO One-on-One Partnering, educational resources to help drive businesses, and insights critical to continuing research and development.

Mr. Shively’s presentation will be available via link anytime globally throughout the week of the conference.

Neumentum:  Addressing a National Health Emergency

Opioid use is considered a critical public health concern in the US.  In 2018, 10.3 million people misused prescription opioid pain relievers[i]. More than 70 million surgical procedures are performed in the U.S. annually and postsurgical pain is routinely treated with opioid analgesics.

Neumentum is dedicated to becoming a leading non-opioid analgesic and neurology specialty pharmaceutical company with product candidates that have the potential to provide the benefits of safe and effective pain management without the limitations and risks for abuse and misuse that come with opioids.  Neumentum’s lead product candidate, NTM-001 (novel, alcohol-free formulation of ketorolac in a pre-mixed bag for continuous IV infusion), has the potential to treat moderately severe acute pain that requires analgesia at the opioid level for up to 24 hours, usually in a postoperative setting, and to reduce the need for opioids. Additionally, NTM-006, a product that is neither an opioid nor a NSAID, has completed positive Phase 2A clinical studies for moderate to moderately severe acute pain. Neumentum is led by a world-wide executive team of biotech and pharmaceutical industry leaders who have extensive experience in pain and neurology, from drug development through commercialization. For more information, visit Neumentum.com.

# # #

INVESTOR CONTACT: 

Scott Shively
CEO & Co-founder
scottshively@neumentum.com
(833) NEUPAIN

 

MEDIA CONTACT:
Patty Leitch
Communications
917-865-0232
patricialeitch@neumentum.com
(833) NEUPAIN

 


[i] CDC website, 2019 National Survey on Drug Use and Health. Mortality in the United States, 2018

[i] CDC website, Scholl L, Seth P, Kariisa M, Wilson N, Baldwin G. Drug and Opioid-Involved Overdose Deaths – United States, 2013-2017. Morb Mortal Wkly Rep. ePub: 21 December 2018)